Most Recent Articles by Da Hee Han, PharmD
The study examined efficacy in 7,441 patients according to a composite outcome score consisting of either the occurrence of asymptomatic or symptomatic proximal deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE), or VTE-related death
The approval for Tafinlar and Mekinist combination therapy was based on a Phase 2 international, multicenter, 3-cohort, non-randomized, non-comparative, open-label trial (Study BRF113928) in patients with locally confirmed stage IV NSCLC with BRAF V600E mutation.
The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease (NEPAD), a new composite endpoint in MS.
The use of contaminated product may cause adverse events such as fever, chills and malaise; more serious adverse events include systemic bacterial sepsis and systemic invasive mycoses.
The human plasma-derived, purified, pasteurized, lyophilized concentrate is derived from large pools of human plasma from U.S. donors.